M2R
0.003
50%
CNJ
0.02
-73.7%
RAD
0.026
44.4%
NAE
0.002
-33.3%
MEM
0.004
33.3%
SPX
0.002
-33.3%
VKA
0.009
28.6%
RKB
0.003
-25%
RDN
0.005
25%
TAR
0.018
-25%
DRO
2.83
23%
OEL
0.004
-20%
NFM
0.017
21.4%
TDO
0.14
-17.6%
4DX
2.95
20.9%
BMO
0.033
-15.4%
VAR
0.006
20%
AX8
0.006
-14.3%
PTX
0.11
18.3%
BNL
0.006
-14.3%
BLU
0.007
16.7%
ECS
0.006
-14.3%
GLL
0.007
16.7%
ENV
0.006
-14.3%
MGL
0.245
16.7%
SER
0.006
-14.3%
VSR
0.035
16.7%
AZY
0.537
-13.4%
EOS
7.44
15.2%
ALM
0.007
-12.5%
BKB
0.8
15.1%
MML
0.028
-12.5%
SNX
0.031
14.8%
PL9
0.007
-12.5%
HPG
1.385
14.5%
SRJ
0.014
-12.5%
CLX
2.15
13.2%
GG1
0.185
-11.9%
MQR
0.009
12.5%
D3E
0.305
-11.6%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

NZ King Salmon inks key government funding partnership

Aquaculture business New Zealand King Salmon (ASX: NZK) has inked a five year funding partnership with the New Zealand government in the duo’s efforts to drive the future of the salmon farming industry in the country.  The collaboration seeks to pilot the technologies that will provide a blueprint for substantive and sustainable salmon farming growth […]

Kelsian charts path for growth as revenue jumps

Land and marine transport specialist Kelsian Group (ASX:KLS) has delivered healthy revenue growth in the first half of the 2025 financial year (H1 FY25) with the company firmly on track to meet its guidance for underlying operating earnings (EBITDA) in the full fiscal year.  All up, revenue jumped by 9.1 per cent year-on-year to surpass […]

Barton Gold (ASX:BGD): Accelerating gold development at Tunkillia project, Gawler Craton, SA

Barton Gold (ASX:BGD) is an Australian gold development company targeting future production of 150,000 ounces of gold per annum from its projects located in the renowned central Gawler Craton of South Australia.Ahead of appearing at the Sydney Mining Club, Barton Gold Managing Director, Alexander Scanlon, joins Lel Smits from The Stock Network. Alexander, welcome to […]

Amplia Therapeutics (ASX:ATX): Ongoing clinical trials developing new treatments for cancer

Amplia Therapeutics (ASX:ATX) is an Australian clinical stage pharmaceutical company focused on developing new approaches for the treatment of cancer and fibrosis through two potent and orally-available inhibitors of Focal Adhesion. Ahead of appearing at the Stocks On Track event, Amplia Therapeutics Chief Executive Officer and Managing Director, Chris Burns, joins Lel Smits on The […]

AdAlta (ASX:1AD): Connecting ‘Eastern’ cellular immunotherapies with ‘Western’ markets

AdAlta (ASX: 1AD) is a clinical stage biotechnology business addressing the need for effective cellular immunotherapies for the treatment of solid cancers. Through its ‘East to West’ strategy, the Company is integrating Asia’s prowess in T cell therapy development with the efficiency and quality of Australia’s clinical and manufacturing ecosystem to create a pathway connecting […]

Guzman y Gomez builds momentum as sales sizzle

Guzman Y Gomez

Mexican restaurant business Guzman Y Gomez (ASX: GYG) has served up a strong set of numbers in the first half of the 2025 financial year (H1 FY25) showcased by a 23 per cent year-on-year improvement in global network sales. Sales and earnings jump All up, the company generated $578 million in global sales during the […]

Universal Store (ASX:UNI): Delivers strong growth as store roll out continues

Youth fashion retailer Universal Store (ASX: UNI) has served up a strong first half of the 2025 financial year (H1 FY25) underpinned by a solid rise in earnings stemming from robust sales growth and an expanding store network. 👟 Total sales of $183.5 million lift by 16.1% from the same time last year 👖 Underlying […]